Intercept Pharmaceuticals, Inc.
NASDAQ:ICPT
19 (USD) • At close November 7, 2023
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 285.71 | 363.468 | 312.69 | 252.002 | 179.804 | 130.956 | 24.951 | 2.782 | 1.742 | 1.622 | 2.446 | 1.805 | 0 |
| Cost of Revenue
| 0.984 | 3.1 | 5.322 | 4.212 | 2.519 | 1.371 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit
| 284.726 | 360.368 | 307.368 | 247.79 | 177.285 | 129.585 | 24.951 | 2.782 | 1.742 | 1.622 | 2.446 | 1.805 | 0 |
| Gross Profit Ratio
| 0.997 | 0.991 | 0.983 | 0.983 | 0.986 | 0.99 | 1 | 1 | 1 | 1 | 1 | 1 | 0 |
| Reseach & Development Expenses
| 176.639 | 185.272 | 191.485 | 242.799 | 207.301 | 191.499 | 153.893 | 128.193 | 80.311 | 27.942 | 16.183 | 11.426 | 12.71 |
| General & Administrative Expenses
| 0 | 0 | 0 | 0 | 255.474 | 0 | 0 | 103.745 | 34.601 | 13.132 | 4.845 | 0 | 0 |
| Selling & Marketing Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -0 | 0.332 | 0 | 0 |
| SG&A
| 176.303 | 230.855 | 332.493 | 317.418 | 255.474 | 273.698 | 273.596 | 103.745 | 34.601 | 13.132 | 5.177 | 4.209 | 3.644 |
| Other Expenses
| 6.521 | 2.155 | 4.414 | 8.89 | 6.771 | 4.516 | 3.904 | 2.727 | 0.776 | 0.1 | -0.104 | 0 | 0.105 |
| Operating Expenses
| 352.942 | 416.127 | 523.978 | 560.217 | 462.775 | 465.197 | 427.489 | 231.938 | 114.912 | 41.073 | 21.36 | 15.636 | 15.864 |
| Operating Income
| -68.216 | -55.759 | -216.61 | -312.427 | -285.49 | -335.612 | -402.538 | -229.156 | -113.17 | -39.452 | -18.914 | -14.875 | -16.353 |
| Operating Income Ratio
| -0.239 | -0.153 | -0.693 | -1.24 | -1.588 | -2.563 | -16.133 | -82.371 | -64.966 | -24.328 | -7.732 | -8.241 | 0 |
| Total Other Income Expenses Net
| -106.642 | -35.667 | -43.64 | -32.254 | -23.752 | -24.755 | -10.292 | 2.727 | -170.056 | -28.34 | -24.729 | 0 | 1.266 |
| Income Before Tax
| -174.858 | -91.426 | -274.88 | -344.681 | -309.242 | -360.367 | -412.83 | -226.429 | -283.226 | -67.792 | -43.644 | -13.83 | -15.087 |
| Income Before Tax Ratio
| -0.612 | -0.252 | -0.879 | -1.368 | -1.72 | -2.752 | -16.546 | -81.391 | -162.587 | -41.805 | -17.843 | -7.662 | 0 |
| Income Tax Expense
| -290.032 | 53.596 | 49.35 | 46.371 | 6.771 | 29.186 | 14.269 | 1.036 | 170.389 | 28.441 | 24.425 | -1.093 | -0.672 |
| Net Income
| 115.174 | -145.022 | -324.23 | -391.052 | -309.242 | -360.367 | -412.83 | -226.429 | -283.226 | -67.792 | -43.644 | -12.738 | -15.087 |
| Net Income Ratio
| 0.403 | -0.399 | -1.037 | -1.552 | -1.72 | -2.752 | -16.546 | -81.391 | -162.587 | -41.805 | -17.843 | -7.056 | 0 |
| EPS
| 3.41 | -4.55 | -9.83 | -12.35 | -10.86 | -14.38 | -16.74 | -9.56 | -13.63 | -3.76 | -6.95 | -3.83 | -4.53 |
| EPS Diluted
| 3.4 | -4.55 | -9.83 | -12.35 | -10.86 | -14.38 | -16.74 | -9.56 | -13.63 | -3.76 | -6.95 | -3.83 | -4.53 |
| EBITDA
| -61.695 | -53.604 | -212.196 | -303.537 | -278.719 | -331.096 | -398.634 | -226.429 | 57.662 | -10.905 | 5.712 | -14.465 | -16.057 |
| EBITDA Ratio
| -0.216 | -0.147 | -0.679 | -1.205 | -1.55 | -2.528 | -15.977 | -81.391 | 33.101 | -6.725 | 2.335 | -8.013 | 0 |